We provide you with 20 years of free, institutional-grade data for SAGE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SAGE. Explore the full financial landscape of SAGE stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Shiferman Gregory L. | Sale | -79 | $9.22 | $728 | 2025-06-26 |
| Quirk Michael C. | Sale | -113 | $9.22 | $1,042 | 2025-06-26 |
| Shiferman Gregory L. | Sale | -176 | $6.91 | $1,216 | 2025-04-11 |
| Shiferman Gregory L. | Grant, award...etc | 525 | 2025-04-11 | ||
| Benecchi Christopher | Sale | -1,454 | $6.91 | $10,047 | 2025-04-11 |
| Benecchi Christopher | Grant, award...etc | 5,967 | 2025-04-11 | ||
| Quirk Michael C. | Sale | -736 | $6.91 | $5,086 | 2025-04-11 |
| Quirk Michael C. | Grant, award...etc | 2,202 | 2025-04-11 | ||
| Greene Barry E | Sale | -4,862 | $6.91 | $33,596 | 2025-04-11 |
| Greene Barry E | Grant, award...etc | 19,964 | 2025-04-11 | ||
| Quirk Michael C. | Grant, award...etc | 2,000 | 2025-04-02 | ||
| Quirk Michael C. | Initial | 2025-04-02 | |||
| Shiferman Gregory L. | Sale | -79 | $8.21 | $649 | 2025-03-26 |
| Shiferman Gregory L. | Sale | -2,502 | $7.49 | $18,740 | 2025-02-25 |
| Shiferman Gregory L. | Sale | -627 | $7.18 | $4,502 | 2025-02-14 |
| Benecchi Christopher | Sale | -822 | $7.18 | $5,902 | 2025-02-14 |
| Gault Laura | Sale | -685 | $7.18 | $4,918 | 2025-02-14 |
| Shiferman Gregory L. | Grant, award...etc | 14,000 | 2025-01-21 | ||
| Benecchi Christopher | Grant, award...etc | 20,000 | 2025-01-21 | ||
| Gault Laura | Grant, award...etc | 24,000 | 2025-01-21 | ||
| Shiferman Gregory L. | Sale | -79 | $5.48 | $433 | 2024-12-27 |
| Benecchi Christopher | Grant, award...etc | 6,250 | 2024-11-14 | ||
| Shiferman Gregory L. | Grant, award...etc | 5,000 | 2024-11-01 | ||
| Shiferman Gregory L. | Initial | 2024-11-01 | |||
| Benecchi Christopher | Sale | -4,755 | $8.96 | $42,605 | 2024-08-07 |
| Benecchi Christopher | Grant, award...etc | 16,200 | 2024-08-07 | ||
| Gault Laura | Sale | -3,288 | $8.96 | $29,460 | 2024-08-07 |
| Gault Laura | Grant, award...etc | 13,500 | 2024-08-07 | ||
| IGUCHI KIMI | Sale | -3,636 | $8.96 | $32,579 | 2024-08-07 |
| IGUCHI KIMI | Grant, award...etc | 13,500 | 2024-08-07 | ||
| Cook Anne Marie | Sale | -4,503 | $8.96 | $40,347 | 2024-08-07 |
| Cook Anne Marie | Grant, award...etc | 13,500 | 2024-08-07 | ||
| Greene Barry E | Sale | -12,273 | $8.96 | $109,966 | 2024-08-07 |
| Greene Barry E | Grant, award...etc | 50,400 | 2024-08-07 | ||
| Benecchi Christopher | Grant, award...etc | 13,500 | 2024-02-15 | ||
| IGUCHI KIMI | Grant, award...etc | 11,250 | 2024-02-15 | ||
| Gault Laura | Grant, award...etc | 11,250 | 2024-02-15 | ||
| Cook Anne Marie | Grant, award...etc | 11,250 | 2024-02-15 | ||
| IGUCHI KIMI | Derivatives Exercise | 1,642 | 2024-01-04 | ||
| Cook Anne Marie | Sale | -1,174 | $19.27 | $22,623 | 2023-11-30 |
| Cook Anne Marie | Grant, award...etc | 4,000 | 2023-11-30 | ||
| JONAS JEFFREY M | Sale | -3,935 | $19.27 | $75,827 | 2023-11-30 |
| JONAS JEFFREY M | Grant, award...etc | 10,000 | 2023-11-30 | ||
| IGUCHI KIMI | Sale | -943 | $19.27 | $18,172 | 2023-11-30 |
| IGUCHI KIMI | Grant, award...etc | 3,500 | 2023-11-30 | ||
| Barrett Elizabeth | Open Market Purchase | 2,000 | $18.64 | 2023-08-11 |
The information provided in this report about SAGE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Sage Therapeutics, Inc(NASDAQ:SAGE) 
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product p...
Website: http://www.sagerx.com
Founded: 2010
Full Time Employees: 675
Sector: Healthcare
Industry: Biotechnology